ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.5153A>G (p.Asn1718Ser) (rs80358739)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000486901 SCV000566491 uncertain significance not provided 2018-02-23 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.5153A>G at the cDNA level, p.Asn1718Ser (N1718S) at the protein level, and results in the change of an Asparagine to a Serine (AAT>AGT). Using alternate nomenclature, this variant would be defined as BRCA2 5381A>G. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Asn1718Ser was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is located within the RAD51 and POLH binding domains (Roy 2012, Buisson 2014). In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether BRCA2 Asn1718Ser is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Ambry Genetics RCV000570495 SCV000668574 likely benign Hereditary cancer-predisposing syndrome 2017-06-29 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Other data supporting benign classification,In silico models in agreement (benign)
Counsyl RCV000113388 SCV000784857 uncertain significance Breast-ovarian cancer, familial 2 2017-01-24 criteria provided, single submitter clinical testing
Invitae RCV000801842 SCV000941640 uncertain significance Hereditary breast and ovarian cancer syndrome 2018-08-13 criteria provided, single submitter clinical testing This sequence change replaces asparagine with serine at codon 1718 of the BRCA2 protein (p.Asn1718Ser). The asparagine residue is weakly conserved and there is a small physicochemical difference between asparagine and serine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in individuals in the Breast Cancer Information Core database (PMID: 10923033). ClinVar contains an entry for this variant (Variation ID: 126062). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The serine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Breast Cancer Information Core (BIC) (BRCA2) RCV000113388 SCV000146548 uncertain significance Breast-ovarian cancer, familial 2 2003-12-23 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.